Gore commences treatment in Europe with new 25 cm VIABAHN Endoprosthesis

NewsGuard 100/100 Score

W. L. Gore & Associates (Gore) announced the treatment of the first European patients with the new 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, the longest length stent-graft available in Europe. Piotr Kasprzak, from the Department of Vascular Surgery at the Klinikum der Universität in Regensburg, Germany, and Thomas Zeller, MD, from the Department of Angiology at the Herz-Zentrum in Bad Krozingen, Germany successfully treated patients using the Gore device.

“The procedure using the GORE VIABAHN Endoprosthesis was very smooth, and the aneurysm was completely excluded”

The new 25 cm GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface is designed to cover more of the lesion in the Superficial Femoral Artery (SFA) potentially reducing the need for multiple devices. Both Dr. Kasprzak and Professor Zeller found the device to be flexible and capable of re-lining tortuous arteries.

"The procedure using the GORE VIABAHN Endoprosthesis was very smooth, and the aneurysm was completely excluded," said Dr. Kasprzak. "Having one long device made the procedure much simpler, and ensured it went efficiently."

"Having a long device is a huge benefit in treating the superficial femoral artery. The 25 cm stent-graft allows the interventionist to efficiently perform an endoluminal bypass of the diseased segment," said Professor Zeller. "The nature of many lesions requires precise placement near the origin of the SFA, and with the GORE VIABAHN Endoprosthesis, I was able to accurately deploy the device."

The manufacturing of the Gore device features a precision laser trimming technology used to remove excess material, resulting in a contoured proximal edge that may improve flow dynamics at the proximal edge. Removal of excess material at the proximal edge improves device apposition to the vessel wall when oversizing prevents device expansion to its nominal diameter. The device also incorporates the PROPATEN Bioactive Surface which utilizes end-point immobilization of derivatized heparin to the endoprosthesis luminal surface. This proprietary surface technology preserves the heparin bioactive sites such that they remain free to interact with the blood at the device surface without being consumed.

The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface is available with a low-profile delivery system that gives interventionalists a more streamlined approach to re-line the peripheral arteries. The GORE VIABAHN Endoprosthesis is constructed with a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure. The excellent flexibility of the GORE VIABAHN Endoprosthesis enables it to better traverse tortuous areas of the SFA and conform more closely to the complex anatomy of the artery.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Physics-based metric predicts aortic aneurysm growth with 98% accuracy